Omeros Corp
OMER3.705USD
+0.095+2.63%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
215.13M시가총액
손실P/E TTM
자세한 내용은 Omeros Corp 회사
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
회사 정보
종목 코드 OMER
회사 이름Omeros Corp
상장일Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
직원 수202
유형Ordinary Share
회계 연도 종료Oct 08
주소201 Elliott Avenue West
도시SEATTLE
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호98119
전화12066765000
웹사이트https://www.omeros.com/
종목 코드 OMER
상장일Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Thu, Jul 17
마지막 업데이트: Thu, Jul 17
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
16.95%
Investment Advisor
15.51%
Hedge Fund
3.93%
Individual Investor
3.84%
Research Firm
3.66%
Bank and Trust
0.89%
Insurance Company
0.13%
Pension Fund
0.10%
Other
55.00%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
251
30.23M
45.04%
-382.24K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Corient Private Wealth LLC
720.42K
1.23%
-13.03K
-1.78%
Mar 31, 2025
Nomura Securities Co., Ltd.
679.02K
1.16%
-68.26K
-9.13%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.44%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Invesco Dynamic Buyback Achievers ETF
0.01%
더 보기
Invesco NASDAQ Future Gen 200 ETF
비율0.44%
Vanguard US Momentum Factor ETF
비율0.12%
iShares Micro-Cap ETF
비율0.04%
ProShares Ultra Nasdaq Biotechnology
비율0.02%
Invesco Nasdaq Biotechnology ETF
비율0.02%
Invesco RAFI US 1500 Small-Mid ETF
비율0.01%
ProShares UltraPro Russell2000
비율0.01%
iShares Russell 2000 Growth ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
Invesco Dynamic Buyback Achievers ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
